Original Article
Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus
M. Arafa,
W. Zohdy,
S. Aboulsoud,
R. Shamloul,
M. Arafa
Department of Andrology, Cairo University, Cairo, Egypt
Search for more papers by this authorW. Zohdy
Department of Andrology, Cairo University, Cairo, Egypt
Search for more papers by this authorS. Aboulsoud
Department of Internal Medicine, Cairo University, Cairo, Egypt
Search for more papers by this authorCorresponding Author
R. Shamloul
Department of Andrology, Cairo University, Cairo, Egypt
Department of Urology, University of Ottawa, Ottawa, Canada
Correspondence
Rany Shamloul, Andrology Department, University of Cairo, Cairo 11742, Egypt.
Tel.: +16 13 761 4500;
Fax: +16 13 761 5305;
E-mail: [email protected]
Search for more papers by this authorM. Arafa,
W. Zohdy,
S. Aboulsoud,
R. Shamloul,
M. Arafa
Department of Andrology, Cairo University, Cairo, Egypt
Search for more papers by this authorW. Zohdy
Department of Andrology, Cairo University, Cairo, Egypt
Search for more papers by this authorS. Aboulsoud
Department of Internal Medicine, Cairo University, Cairo, Egypt
Search for more papers by this authorCorresponding Author
R. Shamloul
Department of Andrology, Cairo University, Cairo, Egypt
Department of Urology, University of Ottawa, Ottawa, Canada
Correspondence
Rany Shamloul, Andrology Department, University of Cairo, Cairo 11742, Egypt.
Tel.: +16 13 761 4500;
Fax: +16 13 761 5305;
E-mail: [email protected]
Search for more papers by this authorSummary
Late-onset hypogonadism (LOH) or age-associated testosterone deficiency syndrome is defined as a clinical and biochemical syndrome associated with advancing age and characterised by symptoms and a deficiency in serum testosterone levels. This condition may result in significant detriment in the quality of life and adversely affect the function of multiple organ systems. It has been suggested that sex steroid hormones may play a causal role in the development of insulin resistance and type II diabetes. This comparative study was aimed at determining the prevalence of LOH in diabetic men with erectile dysfunction and investigating the effect of testosterone replacement therapy on erectile function and on glycaemic control.
References
- Azadzoi KM, Saenz de Tejada I (1991) Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 146: 238–240.
- Azadzoi KM, Goldstein I, Siroky MB, Traish AM, Krane RJ, Saenz de Tejada I (1998) Mechanisms of ischemia-induced cavernosal smooth muscle relaxation impairment in a rabbit model of vasculogenic erectile dysfunction. J Urol 160: 2216–2222.
- Barrett-Connor E (1992) Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 117: 807–811.
- Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106: 581–588.
- Chitaley K, Webb RC (2001) Microtubule depolymerisation facilitates contraction of vascular smooth muscle via increased activation of RhoA/Rhokinase. Med Hypotheses 56: 381–385.
- Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P (2004) Frequent occurrence of hypogonadotropic hypogonadism in type II diabetes. J Clin Endocrinol Metab 89: 5462–5468.
- Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C (2003) Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 104: 195–201.
- Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, Tsiodras S, Dimitriou D, Giamarellou H (2006) Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J Androl 27: 469–477.
- Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mckinlay JB (1994) Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151: 54–61.
- Fung MM, Bettencourt R, Barrett-Connor E (2004) Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 43: 1405–1411.
- Giuliano FA, Leriche A, Jaudinot EO, Solesse de Gendre A (2004) Prevalence of erectile dysfunction among 7,689 patients with diabetes or hypertension, or both. Urology 64: 1196–1201.
- Goodman-Gruen D, Barrett-Connor E (2000) Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 23: 912–918.
- Guay AT, Velasquez E, Perez JB (1999) Characterization of patients in a medical endocrine-based center for male sexual dysfunction. Endocr Pract 5: 314–321.
- Haffner SM (2000) Sex hormones, obesity, fat distribution, type II diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord 24 (Suppl 2): S56–S58.
- Hall SA, Kupelian V, Rosen RC, Travison TG, Link CL, Miner MM, Ganz P, McKinlay JB (2009) Is hyperlipidemia or its treatment associated with erectile dysfunction? Results from the Boston Area Community Health (BACH) Survey. J Sex Med 6: 1402–1413.
- Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S (2001) The Aging Males’ Symptoms (AMS) rating scale. Cultural and linguistic validation into English. Aging Male 3: 14–22.
10.1080/713604576 Google Scholar
- Henry GD, Byrne R, Hunyh TT, Abraham V, Annex BH, Hagen PO, Donatucci CF (2000) Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study. Int J Impot Res 12: 334–339.
- Jaffe A, Chen Y, Kisch ES, Fischel B, Alon M, Stern N (1996) Erectile dysfunction in hypertensive subjects. Assessment of potential determinants. Hypertension 28: 859–862.
- Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 163: 460–463.
- Kang KK, Yu JY, Yoo M, Kwon JW (2005) The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res 17: 409–416.
- Kapoor D, Goodwin E, Channer KS, Jones TH (2006) Testosterone replacement therapy improves insulin resistance, glycemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type II diabetes. Eur J Endocrinol 6: 899–906.
- Kim SC, Kim IK, Seo KK, Baek KJ, Lee MY (1997) Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits. Urol Res 25: 341–346.
- Laaksonen DE, Niskanen L, Punnonen K, Nyysso¨nen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT (2003) Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149: 601–608.
- Lehman TP, Jacobs JA (1983) Etiology of diabetic impotence. J Urol 129: 291–294.
- Malkin CJ, Pugh PJ, Kapoor D, Jones RD, Channer KS, Jones TH (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89: 3313–3318.
- Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P (1992a) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16: 991–997.
- Marin P, Krotkiewski M, Bjorntorp P (1992b) Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1: 329–336.
- Mersdorf A, Goldsmith PC, Diederichs W, Padula CA, Lue TF, Fishman IJ, Tanagho EA (1991) Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J Urol 145: 749–758.
- Metro MJ, Broderick GA (1999) Diabetes and vascular impotence: does insulin dependence increase the relative severity? Int J Impot Res 11: 87–89.
- National Institute for Health and Clinical Excellence (2008) Management of Type II Diabetes (update) – Management of Blood Glucose (Guideline 6–11). NICE, London.
- Nikoobakht M, Nasseh H, Pourkasmaee M (2005) The relationship between lipid profile and erectile dysfunction. Int J Impot Res 17: 523–526.
- Ohl JY, Barrett-Connor E, Wedick NM, Wingard DL (2002) Endogenous sex hormones and the development of type II diabetes in older men and women. Diabetes Care 25: 55–60.
- Phillips GB, Jing TY, Resnick LM, Barbagallo M, Laragh JH, Sealey JE (1993) Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension. J Hypertens 11: 699–702.
- Phillips GB, Jing T, Heymsfield SB (2003) Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 52: 784–790.
- Pugh PJ, Jones TH, Channer KS (2003) Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24: 909–915.
- Roumeguere T, Wespes E, Carpentier Y, Hoffmann P, Schulman CC (2003) Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 44: 355–359.
- Ryu JK, Shin HY, Song SU, Oh SM, Piao S, Han JY, Park KW, Suh JK (2006) Downregulation of angiogenic factors and their downstream target molecules affects the deterioration of erectile function in a rat model of hypercholesterolemia. Urology 67: 1329–1334.
- Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA (1989) Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 320: 1025–1030.
- Sairam K, Kulinskaya E, Boustead GB, Hanbury DC, McNicholas TA (2001) Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int 88: 68–71.
- Sarica K, Arikan N, Serel A, Arikan Z, Aytac S, Culcuoglu A, Bayram F, Yaman LS, Kupeli S (1994) Multidisciplinary evaluation of diabetic impotence. Eur Urol 26: 314–318.
- Seftel AD, Sun P, Swindle R (2004) The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 171: 2341–2345.
- Selvin E, Burnett AL, Platz EA (2007) Prevalence and risk factors for erectile dysfunction in the US. Am J Med 120: 151–157.
- Shamloul R, Ghanem H, Abou-zeid A (2004) Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res 16: 452–455.
- Shukla N, Jones R, Persad R, Angelini GD, Jeremy JY (2005) Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolemic rabbits. Eur J Pharmacol 517: 224–231.
- Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L (1992) Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 35: 173–177.
- Simon D, Charles MA, Lahlou N, Nahoul K, Oppert JM, Gouault-Heilmann M, Lemort N, Thibult N, Joubert E, Balkau B, Eschwege E (2001) Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone. Diabetes Care 24: 2149–2151.
- Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS (2001) The effects of induced hypogonadism on arterial stiffness, body composition and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86: 4261–4267.
- Tomova A, Kumanov P (2005) Are dehydroepiandrosterone sulphate and lipids associated with erectile dysfunction? Maturitas 50: 294–299.
10.1016/j.maturitas.2004.07.001 Google Scholar
- Tripathy D, Shah P, Lakshmy R, Reddy KS (1998) Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res 30: 642–645.
- Vermeulen A, Kaufman JM, Deslypere JP, Thomas G (1993) Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 76: 1140–1146.
- Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS (2004) Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89: 534–543.
- Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Thompson IM, Weidner W, Wu CW (2008) Investigations, treatment and monitoring of late onset hypogonadism in males. ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159: 507–514.
- Whitehead ED, Klyde BJ (1990) Diabetes-related impotence in the elderly. Clin Geriatr Med 6: 771–795.
- Xie D, Pippen AM, Odronic SI, Annex BH, Donatucci CF (2006) Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit. J Sex Med 3: 223–232.
- Xu T, Wang X, Hou S, Zhu J, Zhang X, Huang X (2002) Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer. Chin Med J 115: 1336–1340.
- Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P, Chotkowska E, Srzednicki M, Sadowski Z (1996) Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121: 35–43.
- Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS (1990) Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 71: 929–931.
